Open AccessClopidogrel or ticagrelor alongside dabigatran in acute coronary syndrome and indication for NOAC: a study rationale
Author(s) -
Jasper Luijkx,
P J C Winkler,
Arnoud W J van 't Hof
Publication year - 2022
Publication title -
future cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.392
H-Index - 33
eISSN - 1744-8298
pISSN - 1479-6678
DOI - 10.2217/fca-2021-0085
Subject(s) - medicine , clopidogrel , ticagrelor , acute coronary syndrome , dabigatran , percutaneous coronary intervention , cardiology , aspirin , atrial fibrillation , myocardial infarction , warfarin
The combination of oral anticoagulants with platelet inhibitors has been widely investigated in patients with coronary stenting and concomitant atrial fibrillation. In these patients, default therapy after percutaneous coronary intervention in acute coronary syndrome is clopidogrel plus non-vitamin K antagonist oral anticoagulant, omitting aspirin. However, in view of the high thromboembolic risk associated with acute coronary syndrome and the number of poor metabolizers for clopidogrel, investigation of alternative P2Y12-inhibitors is mandatory. This prospective, multicenter, open-label, registry-based, randomized, controlled trial aims to show the non-inferiority of dabigatran plus ticagrelor versus dabigatran plus clopidogrel in patients on chronic anticoagulants who undergo percutaneous coronary intervention in acute coronary syndrome. The primary end point is major bleeding as defined by the Bleeding Academic Research Consortium bleeding definition. Trial registration number: NL75644.096.21